Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
The chart shows the growth of an initial investment of $10,000 in Vir Biotechnology, Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Vir Biotechnology, Inc. Common Stock (VIR) has returned 50.25% so far this year and 73.56% over the past 12 months. Looking at the last ten years, VIR has achieved an annualized return of -5.62%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Vir Biotechnology, Inc. Common Stock (VIR) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.38% | 24.01% | 1.24% | -0.44% | ||||||||
| 2025 | 39.60% | -17.66% | -20.88% | -4.67% | -19.28% | 2.65% | 1.60% | -1.20% | 16.77% | 4.20% | 8.63% | -3.05% |
| 2024 | -6.00% | 19.07% | -10.59% | -16.57% | 21.54% | -15.80% | 15.32% | -17.40% | -8.10% | 0.67% | 11.48% | -7.44% |
| 2023 | 15.70% | -22.42% | 2.56% | 8.71% | 6.85% | -4.44% | -42.32% | -10.02% | -26.80% | -15.46% | 19.52% | 6.91% |
| 2022 | -17.87% | -27.46% | 2.92% | -21.22% | 27.77% | 0.55% | 10.36% | -14.54% | -18.41% | 13.30% | 26.04% | -8.36% |
| 2021 | 135.03% | -6.38% | -19.54% | -8.39% | -13.09% | 10.65% | -23.50% | 44.13% | -13.74% | 0.08% | 25.68% | -4.42% |
| 2020 | 112.02% | 72.86% | -13.31% | -7.69% | 15.32% | 20.50% | 23.57% | -15.54% | -13.07% | -10.15% | 1.11% | -17.75% |
| 2019 | -12.69% | -15.25% | 4.88% |
The charts below present risk-adjusted performance metrics for Vir Biotechnology, Inc. Common Stock (VIR) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of VIR compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Vir Biotechnology, Inc. Common Stock volatility is 3.27%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.00B | 1.92B | 2.80B | 1.95B | 918.76M | 512.07M |
| Equity Attributable To Parent (USD) | 765.28M | 1.59B | 2.08B | 1.43B | 716.85M | 423.94M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - |
| Equity (USD) | 765.28M | 1.59B | 2.08B | 1.43B | 716.85M | 423.94M |
| Noncurrent Liabilities (USD) | 144.73M | 153.42M | 213.10M | 181.18M | 102.85M | 28.92M |
| Other Current Liabilities (USD) | 83.01M | 169.07M | 504.61M | 334.72M | 93.99M | 53.33M |
| Accounts Payable (USD) | 9.80M | 6.33M | 6.42M | 6.52M | 5.08M | 5.88M |
| Current Liabilities (USD) | 92.82M | 175.41M | 511.03M | 341.24M | 99.06M | 59.21M |
| Liabilities (USD) | 237.55M | 328.82M | 724.13M | 522.42M | 201.91M | 88.13M |
| Other Non-current Assets (USD) | 425.27M | 212.25M | 144.65M | 315.33M | 94.63M | 57.07M |
| Intangible Assets (USD) | 7.85M | 22.57M | 32.76M | 33.29M | 33.82M | 35.69M |
| Fixed Assets (USD) | 55.62M | 96.02M | 105.61M | 42.83M | 17.95M | 16.31M |
| Noncurrent Assets (USD) | 488.74M | 330.83M | 283.01M | 391.45M | 146.40M | 109.08M |
| Other Current Assets (USD) | - | - | 119.08M | 653.32M | 35.47M | - |
| Cash (USD) | - | 1.63B | 2.40B | 909.50M | 736.90M | - |
| Current Assets (USD) | 514.08M | 1.59B | 2.52B | 1.56B | 772.37M | 403.00M |
| Assets (USD) | 1.00B | 1.92B | 2.80B | 1.95B | 918.76M | 512.07M |
U.S. stock futures rose on Tuesday following Monday's sell-off triggered by AI-related economic concerns and deflationary depression fears. Major indices showed modest gains in premarket trading. Key movers included Keysight Technologies surging 16% on strong earnings, Vir Biotechnology jumping 63% on revenue beat, and Whirlpool plunging 7.5% after announcing an $800 million stock offering. Market sentiment remains cautious amid Trump's tariff threats and geopolitical tensions.
Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.
Vir Biotechnology reported a Q2 2025 net loss of $0.80 per share, with revenues of $1.2 million. The company advanced its clinical pipeline in hepatitis delta and oncology, maintaining $892.1 million in cash reserves while continuing to invest in research and development.
GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
Across the recent three months, 5 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $71.4, a high estimate of $110.00, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 614.0% from the previous average price target of $10.00. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Vir Biotechnology by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Eric Joseph JP Morgan Raises Neutral $12.00 $10.00 Joseph Stringer Needham Maintains Buy $15.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to ...Full story available on Benzinga.com
Across the recent three months, 6 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 2 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 1 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $61.17, a high estimate of $110.00, and a low estimate of $10.00. This current average has increased by 76.43% from the previous average price target of $34.67. Breaking Down Analyst Ratings: A Detailed Examination In examining recent analyst actions, we gain insights into how financial experts perceive Vir Biotechnology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Eric Joseph JP Morgan Raises Neutral $12.00 $10.00 Joseph Stringer Needham Maintains Buy $15.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $110.00 - Eric Joseph JP Morgan Raises Neutral $10.00 $9.00 Patrick Trucchio HC Wainwright & Co. Raises Buy $110.00 $85.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it ...Full story available on Benzinga.com
Vir Biotechnology (VIR) delivered earnings and revenue surprises of 51.52% and 250.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).